Latest stories
Story · 1 report
Early progress on accelerating drug development with Claude
Anthropic has formed drug-development research partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, while also acquiring rare-disease startup Mithril Medicine. The company is using Claude across target assessment, molecule design, laboratory-data analysis, manufacturing documentation, regulatory filings and clinical-trial planning. Most of the work remains preclinical, meaning the candidate drugs have generally not yet been tested in humans. In one Generate Biomedicines project, Claude Code helped design a CAR T-cell genetic component about 70% shorter than a standard version; Generate reported that lab tests produced roughly 10 times as many cancer-recognizing receptors and improved tumor-cell killing. Divergence Labs used Claude to generate about 35,000 antibody designs in a month for food-allergy treatment, identifying early binding and IgE-dislodging candidates. BigHat tested roughly 1,010 Claude-guided antibody-fragment variants in 10 weeks, reporting improvements including more than 10-fold tighter binding and over 100-fold slower clumping. Enveda reported that Claude found all 11 documentation issues detected by human reviewers plus seven additional issues across 1,061 pages, reducing review time from more than 25 hours to under three. Anthropic plans to expand clinical-trial work with Bristol Myers Squibb in 2027. Mithril’s founder used Claude to coordinate work with 11 external labs; Anthropic expects a muscular-dystrophy candidate could be ready for human clinical trials as soon as late 2028 if results continue to hold up.
anthropic.com
🔥🔥🔥🔥🔥2 min summary
10/27/2026
Story · 1 report
Claude designed protein binders against scorpion neurotoxins
Anthropic used an internal Claude research model to design small protein binders for five scorpion-venom neurotoxins, with the long-term goal of supporting antivenom development. Over 64 hours and four follow-up prompts, Claude generated 318,484 candidate proteins, screened 553,052 protein-toxin pairs, and selected 180 designs for laboratory testing. Anthropic added 31 more designs with Claude’s help, and Adaptyv Bio and Twist Bioscience tested all 211 candidates. Seventeen designs met Anthropic’s binding criteria, which required consistent results from both laboratories, dissociation constants of 1 µM or tighter, and no detectable binding to an unrelated human protein. The binders each targeted a single toxin: seven bound Cn2, four bound AaH II, four bound AaH I, and two bound LqhIII. No designs intended to bind multiple toxins met the criteria for more than one target. The strongest Cn2 binders, Cn2-B1 and Cn2-B2, showed single-digit nanomolar affinity and competed with an antibody reported to neutralize Cn2 in mice. The results establish binding to recombinant toxins, not venom neutralization. Anthropic has not tested the designs in cells or animals and does not claim to have produced an antivenom. It released all 211 designs and their experimental data for further research.
anthropic.com
🔥🔥🔥🔥🔥1 min summary
10/20/2026
No more articles to load

